Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda Therapeutics closed a funding round that valued the company at $2 billion. The AI biotech is conducting clinical trials on drugs designed to treat skin conditions and maintain weight loss in patients who have discontinued GLP-1 medications.

Next story